GlassScriptPhysician profile
Dennis D Palmer
NPI 1609920768
$3,225.92
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $406 · 2021: $332 · 2022: $285 · 2023: $859 · 2024: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $330.77 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.65 | 2019-2024 | Jardiance |
| Amgen INC. | $308.21 | 2019-2024 | Prolia, Evenity |
| Pfizer INC. | $266.03 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $263.37 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $234.33 | 2021-2024 | |
| Exact Sciences Corporation | $142.59 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $125.54 | 2022-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $117.82 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Novo Nordisk INC | $104.29 | 2019-2023 | Rybelsus, Ozempic |
| Allergan, INC. | $96.33 | 2019-2020 | |
| Lilly USA, LLC | $80.02 | 2019-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $75.04 | 2019-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $70.95 | 2021-2024 | Eliquis |
| Esperion Therapeutics, INC. | $61.16 | 2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.